Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03411915 | A Study of XmAb®18087 in Subjects With NET and GIST | PHASE1 | COMPLETED | 62 | — | — | Jan 22, 2018 | Oct 26, 2021 | May 10, 2022 | 16 | United States |
Treatment-related adverse events as assessed by CTCAE v4.03
Establishing a safe and tolerable dose of XmAb18087 administered by intravenous (IV) dosing in NET and GIST patients
| Arm | Type | Description |
|---|---|---|
| XmAb18087 | EXPERIMENTAL | XmAb18087 administered on days 1, 8, 15, and 22 of each 28-day cycle for a total of 3 cycles |
| Name | Type | Description |
|---|---|---|
| XmAb18087 | BIOLOGICAL | monoclonal bispecific antibody |
Inclusion Criteria: * Histologically or cytologically confirmed well differentiated low or intermediate grade (World Health Organization \[WHO\] Grade 1 or 2) NET of pancreatic, gastrointestinal, lung, or undetermined origin that is locally advanced or metastatic and has progressed within the past ...